<DOC>
	<DOCNO>NCT00532220</DOCNO>
	<brief_summary>BACKGROUND : Bone marrow edema ( BME ) knee occur localized inflammatory disease relation spontaneous non-traumatic osteonecrosis ( ON ) . Prognosis BME/ON course knee arthroscopy appear poor case result knee arthroplasty . Treatment option ON depend general size lesion . Smaller lesion manage mechanical unloading use non-steroidal anti-inflammatory drug , large lesion general require osteotomy arthroplasty . In animal study show bisphosphonates prevent resorption necrotic bone ischemic necrosis revascularization . In human , bisphosphonate treatment use successfully bone marrow oedema avascular necrosis femoral head . In observational study use bisphosphonates ( ibandronate , pamidronate ) patient either spontaneous ( believe ) arthroscopy-induced BME knee significant rapid sustain pain relief observe mean decrease pain scale visual analogue scale 60 % 3 month 80 % 6 month . Our experience suggest apparent beneficial effect amino-bisphosphonates treatment BME knee . AIM : This randomize , double-blind , placebo-controlled study aim provide data clinical , biochemical radiological outcome patient bone marrow edema relation spontaneous arthroscopy-induced ON knee treat ibandronate placebo . ENDPOINTS : The primary objective demonstrate superiority treatment ibandronate compare placebo regard clinical outcome ( pain [ VAS score ] ) spontaneous arthroscopy-induced BME/ON knee 12 week . Secondary objective include ) clinical outcome ( pain [ VAS score ] ) 24 week , b ) evaluation radiological outcome ( MRI scan ) 12 48 week , c ) change biochemical marker bone turnover , ) number salvage therapy need case persistence observe placebo therapy . METHODS : The study design single-center , randomize double-blind , placebo-controlled trial . A total number 30 patient BME/ON recruit . Each patient randomize 1:1 ratio receive ibandronate IV placebo IV . Additionally , patient receive 500 mg calcium 400 IU vitamin D per day throughout study , diclofenac/esomeprazole initial 3 month ( blind treatment duration 24 week ) . Baseline follow-up data collection contain variable need evaluation clinical , biochemical radiological evaluation treatment efficacy . EXPECTED RESULTS : We hypothesize treat patient BME/ON knee , therapy ibandronate superior reduce pain , radiological finding compare placebo .</brief_summary>
	<brief_title>Study Into Effect Ibandronate Treatment Bone Marrow Edema Relation Spontaneous Non-traumatic Osteonecrosis Knee : A Randomized Double-blind , Placebo-controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Consecutive patient newly diagnose BME relation ON , confirm MRI scan Baseline renal insufficiency ( calculated creatinine clearance &lt; 50 ml/min ) Baseline hypocalcemia ( serum calcium &lt; 2.0 mmol/l ) Premenopausal woman without adequate contraception Hypersensitivity bisphosphonates Prior treatment bisphosphonates within last 2 year prior randomization Prior treatment calcitonin within last month prior randomization Treatment investigational drug within 30 day prior randomization Any medical psychiatric condition , opinion investigator , would preclude participant adhere protocol complete trial per protocol Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>osteonecrosis</keyword>
	<keyword>bone marrow edema</keyword>
	<keyword>ibandronate</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>knee</keyword>
</DOC>